Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gout & Excess Risk of Severe SARS-CoV-2 Infection

Arthritis & Rheumatology  |  January 3, 2023

Background & Objectives

Patients with gout often have multiple comorbidities, making them susceptible to SARS-CoV-2 infection and poor outcomes. Xie et al. set out to examine the association between gout and the risk of SARS-CoV-2 infection and severe outcomes, especially in patients vaccinated against COVID-19. By identifying individuals who are susceptible to breakthrough COVID-19 and severe outcomes despite vaccination, doctors may identify populations who would benefit from other risk-mitigating strategies (e.g., pre-exposure prophylaxis).

Methods

Xie et al. conducted two cohort studies using The Health Improvement Network (THIN) in the U.K. The database consists of ~17 million individuals from 790 general practices whose healthcare information is systematically recorded by general practitioners and sent anonymously to THIN. Individuals with gout and those without gout from the general population were followed up from Dec. 8, 2020 to Oct. 31, 2021. Xie et al. estimated the rate difference and hazard ratio (HR) of SARS-CoV-2 infection and severe outcomes (i.e., hospitalization and death within 30 days after SARS-CoV-2 infection) for individuals with gout vs. those without gout using a Cox proportional hazards model according to SARS-CoV-2 vaccination status. The researchers adjusted for potential confounders by using overlap weighting of exposure scores.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results

Among the vaccinated cohort, 1,955 cases of breakthrough COVID-19 infection occurred in individuals with gout (4.68 cases per 1,000 person-months), and 52,468 cases occurred in 1,336,377 individuals without gout (3.76 cases per 1,000 person-months). The adjusted rate difference of breakthrough infection was 0.91 cases per 1,000 person-months (95% confidence interval [CI] 0.62–1.20 cases per 1,000 person-months), and the adjusted HR was 1.24 (95% CI 1.19–1.30). Based on these data, gout was also associated with an increased risk of hospitalization and death. Women with gout also exhibited an increased risk of hospitalization and death. Similar associations with gout were observed in the unvaccinated cohort.

Conclusions

In this large, population-based study, Xie et al. found that the risks of SARS-CoV-2 infection, 30-day hospitalization and 30-day death were higher among individuals with gout than individuals without gout in the general population, irrespective of COVID-19 vaccination status. In addition, women with gout may be more susceptible to severe outcomes of COVID-19 (i.e., hospitalization and death) than men with gout. These findings suggest that additional measures should be considered to mitigate the risk of SARS-CoV-2 infection and potential severe outcomes for individuals with gout, especially women and even after vaccination.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For full study details, including source material, refer to the full article. 

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis & RheumatologycomorbiditiesCOVID-19GoutGout Resource CenterResearchrisk

Related Articles

    The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

    November 23, 2021

    New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

    Research Helps Explain Idiosyncrasies of COVID-19

    November 23, 2021

    The Basic and Clinical Research Conference session on Rheumatology Complications of Emerging Viral Infections/SARS-CoV-2 presented findings from numerous studies that help explain some of the idiosyncrasies of COVID-19.

    COVID-19 Vaccine Efficacy & Safety Discussed at Town Hall

    August 20, 2021

    At a recent ACR town hall, panelists described immune responses and side effects of COVID-19 vaccination in patients with rheumatic disease, along with ways to leverage monoclonal antibody treatments, especially in light of virus variants.

    Serological Antibody Tests in COVID-19: Test Reliability and Utility

    June 10, 2020

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences